This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

UPC clarifies inventive step standard in Amgen–Sanofi appeal case

By Inbar Preiss ( November 26, 2025, 10:34 GMT | Insight) -- Amgen won a dispute over its cholesterol-lowering patent as UPC appeal court judges restored it and clarified the court’s inventive-step test, confirming the “realistic starting point” approach and rejecting Sanofi’s attempt to revoke the patent.Sanofi has lost its bid to revoke Amgen’s cholesterol-lowering patent after the Unified Patent Court’s top judges ruled that it involved an inventive step, overturning an earlier decision by the UPC's Munich Central Division....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login